Answers are grounded in this paper and cite their sources.
Demonstrates cost-effectiveness of vaccination in adults aged 54 and older, suggesting improved economic value.
Recombinant zoster vaccine remained economically favorable for adults 60 years and older, but routine vaccination at age 50 was not cost-effective under updated assumptions.2. Vaccination became cost-effective at approximately age 54, suggesting that initiation in the mid-50s or later may provide better economic value.
No takes yet. Share an insight, caveat, or question.
Yue et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: